Evolocumab(PCSK9抑制剂)的临床药代动力学与药效学
Evolocumab是一种人源单克隆免疫球蛋白G2,特异性结合PCSK9以降低LDL-C,呈非线性动力学,有效半衰期为11-17天。皮下140mg每2周或420mg每月一次可使LDL-C降低约55-75%,且无需根据患者因素或合并用药调整剂量。
要点
- Evolocumab与PCSK9饱和结合呈非线性消除,有效半衰期11-17天
- 140mg Q2W或420mg QM皮下给药降低LDL-C约55-75%
- 轻中度肝损、肾损、体重、种族、性别、年龄无需剂量调整
核心结论
- Evolocumab通过特异性结合PCSK9降低LDL-C,呈非线性药代动力学,有效半衰期11-17天。
- 皮下140mg Q2W或420mg QM降低LDL-C约55-75%,且无需根据患者因素或合并用药调整剂量。
研究设计与样本
- 综述了Evolocumab的临床药代动力学与药效学特征,基于多项临床研究数据。
主要发现
- Evolocumab对PCSK9的抑制作用快速,4小时内达最大抑制。
- 稳态下,140mg Q2W给药后约1周LDL-C降低达峰,420mg QM给药后约2周达峰,并在给药间期内回落至基线。
- 多项临床研究中,上述剂量较安慰剂降低LDL-C约55-75%。
- Evolocumab还降低脂蛋白(a)水平并改善其他血脂指标。
- 轻中度肝损、肾损或肾衰竭、体重、种族、性别、年龄对LDL-C药效学无临床意义差异。
关键数值与推荐
- 有效半衰期为11-17天。
- 皮下140mg Q2W或420mg QM降低LDL-C约55-75%(与安慰剂比较)。
- 无需根据患者特异性因素或合并用药调整剂量。
临床怎么用
- 临床可按140mg每2周或420mg每月一次皮下给药,无需因肝肾功能、体重、种族、性别、年龄或合并用药调整剂量。
- 单用或与他汀联用均有额外LDL-C降低作用,联用时LDL-C进一步下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kinetics as a result of binding to PCSK9. Elimination is predominantly through saturable binding to PCSK9 at lower concentrations and a nonsaturable proteolytic pathway at higher concentrations. The effective half-life of evolocumab is 11-17 days. The pharmacodynamic effects of evolocumab on PCSK9 are rapid, with maximum suppression within 4 h. At steady state, peak reduction of LDL-C occurs approximately 1 week after a subcutaneous dose of 140 mg every 2 weeks (Q2W) and 2 weeks after a subcutaneous dose 420 mg once monthly (QM), and returns towards baseline over the dosing interval. In several clinical studies, these doses of evolocumab reduced LDL-C by approximately 55-75% compared with placebo. Evolocumab also reduced lipoprotein(a) [Lp(a)] levels and improved those of other lipids in clinical studies. No clinically meaningful differences in pharmacodynamic effects on LDL-C were observed in adult subjects regardless of mild/moderate hepatic impairment, renal impairment or renal failure, body weight, race, sex, or age. No clinically meaningful differences were observed for the pharmacodynamic effects of evolocumab on LDL-C between patients who received evolocumab alone or in combination with a statin, resulting in additional lowering of LDL-C when evolocumab was combined with a statin. No dose adjustment is necessary based on patient-specific factors or concomitant medication use.
引用
- Kasichayanula S, Grover A, Emery MG, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018. PMID: 29353350. doi:10.1007/s40262-017-0620-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。